MicroVue CIC-C1q EIA
Quidel CorporationAn EIA for the detection of Circulating Immune Complexes via C1q binding in human serum, plasma and other biological or experimental samples
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well being of people around the globe with well known and respected products that provide healthcare professionals with accurate and cost-effective diagnostic information at the point of care (POC). Our core competencies and capabilities include: Immunoassay development and automated manufacturing Lateral Flow (LF): infectious disease, women's health Direct Fluorescent Antibodies (DFA) : infectious disease, virology Microtiter: bone and complement pathway markers Monoclonal antibody characterization and development Molecular assay development We sell our products to professionals for use in physician's offices, hospitals, clinical and reference laboratories, wellness screening centers, and retail clinics. Quidel commenced operations in 1979 and we launched our first products, dipstick-based pregnancy tests, in 1984. Our product base and technology platforms have expanded through internal development and acquisitions of other products and technologies. The current product areas are infectious diseases, pregnancy, herpes, Graves' Disease, autoimmune diseases and osteoporosis, for professional and research use. During the early 1990's, Quidel successfully embarked on a mission to build its own branded business and market franchises in the professional use markets. As a result, sales are primarily driven by our branded business under the QuickVue® brand name, and the Company enjoys excellent product recognition in its target markets. In early 2010, the Company acquired Diagnostic Hybrids (DHI) as part of a continued focus on increasing its research and development efforts to accelerate the rate of new product introductions. The strength of Quidel's brand equity is reflected in the success of QuickVue® in markets around the world. We are extending the QuickVue® brand in select Asian and European markets. We sell through sales representatives for Europe, Middle East, Africa, Asia-Pacific, Latin America and, other international locations, by channeling products through distributor organizations and sales agents. We market our products in the U.S. through a network of national and regional distributors, supported by a direct sales force, and were pleased to be recognized by three of the largest U.S. medical supply distributors as "Supplier of the Year" within the last year.
An EIA for the detection of Circulating Immune Complexes via C1q binding in human serum, plasma and other biological or experimental samples
An EIA for the detection of functional C1 inhibitor in human serum, plasma and other biological or experimental samples
An EIA for the detection of Deoxypyridinoline crosslinks (DPD) in human urine
An EIA for the detection of Intact Parathyroid Hormone (PTH) in human serum and plasma
An enzyme immunoassay for the quantitation of sclerostin in human serum and plasma.
An EIA for the detection of Pyridinium crosslinks (PYD) in human urine
An EIA for the detection of Bone Alkaline Phosphatase (BAP) in human serum
Immunoassay that measures intact osteocalcin (OC) in serum samples.
Serum based assay that measures the caroboxyterminal propeptide of type 1 collagen (CICP) that reflects production of type 1 collagen.
Colormetric microwell assay for the quantitative determination of Creatinine in urine specimens based upon the Jaffe method.
A quantitative assay that measures pyridinium (PYD) crosslinks of type 1 collagen in serum.
ELISA test to measure YKL-40, also known as human cartilage 39 (HC gp-39), in serum and human cell cultures.
Enzyme immunoassay for the quantitative determination of type 1 collagen alpha 1 helical peptide 620-633 in urine specimens.
Immunoassay kit that consists of reagents and controls for assaying total deoxypyridinoline (DPD) crosslinks in serum or urine.
An EIA for the detection of Tartrate-resistant acid phosphatase 5b (TRAP5b) in rat serum
An EIA for the detection of Osteoprotegerin (OPG) in human serum, plasma and other experimental samples
An EIA for the detection of Tartrate-resistant acid phosphatase 5b (TRAP5b) in human serum and plasma
An EIA for the detection of Hyaluronic Acid in human urine, serum, and other biological or experimental samples
An EIA for the detection of Circulating Immune Complexes in human serum, plasma and other biological or experimental samples
An EIA for the measurement of classical pathway hemolytic activity in human serum
An EIA for the detection of Bb in human serum, plasma and other biological or experimental samples
EIA for C3 activation. iC3b is generated during the activation of the complement system via the classical or alternative pathway.
EIA for measurement of C4d-containing fragments and classical pathway activation.
An enzyme immunoassay that measures the amount of the SC5b-9 complex present in human plasma or serum specimens.
An EIA for the detection of C5a (C5a des-Arg) in human serum, plasma and other biological or experimental samples